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 There is no consensus over how best to measure long-term control of atopic dermatitis in clinical trials
 To date, repeated measurement of eczema severity, assessment of flares and use of atopic dermatitis
medications have all been used.
 Consensus agreement of core outcome sets for atopic dermatitis will improve evidence-based practice.
1Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardised methods for1
capturing long-term control of AD.2
Objective: To identify how long-term control has been captured in published randomised controlled trials (RCTs). Results3
will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.4
Methods: Systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of ≥3 5 
months, at least one outcome measure recorded at ≥3 time-points, full paper available, and published in English.  6 
Results: 101/ 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD7
outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%); and AD flares/remissions (26 RCTs; 25.7%).8
Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often9
failed to make best use of the data. Time to first flare was most commonly for trials including flare data (21/52).10
Medication-use was recorded based on quantity, potency and frequency of application.11
Limitations: Included RCT data only12
Conclusion: This review illustrates the difficulties in measuring long-term control, and points to the need for improved13
harmonization of outcomes.14
15
2Abbreviations16
AD, Atopic Dermatitis17
ANOVA, Analysis of Variance18
ANCOVA, Analysis of Covariance19
BSA, Body Surface Area20
EASI, Eczema Area and Severity Index)21
IGA, Investigators Global Assessment22
HOME, Harmonizing Outcome Measure for Eczema23
POEM, Patient-Oriented Eczema Measure24
RTC, Randomised Controlled Trial25
26
27
3INTRODUCTION28
Atopic dermatitis) (syn. atopic eczema) is a highly prevalent, itchy, inflammatory skin condition that affects29
children and adults. As with other chronic inflammatory diseases, AD severity tends to wax and wane over30
time, with periods of relative remission, interspersed with periods of increased disease activity or “flare”.1 AD31
treatments aim to reduce disease intensity and minimise the number of flares and increase the duration of32
remissions. The ability to measure long-term control of AD over time is an important outcome when evaluating33
effectiveness of treatments, as this reflects patients’ experiences of living with the condition, and long term34
control has been identified as a core outcome to be included in future AD clinical trials2.35
To date, there is little consensus over how best to capture long-term control in AD. Two systematic reviews36
have demonstrated the variability in AD flare definitions used in published studies,3, 4 and have highlighted the37
methodological challenges in capturing AD flares. Other approaches to capture long-term control include38
measurement of anti-inflammatory medication-use over time, or the repeated measurement of AD severity39
and other health outcomes.40
The Harmonizing Outcome Measure for Eczema (HOME) initiative (www.homeforeczema.org) identified long-41
term control as one of four key domains to measure in all clinical trials in AD. The current systematic review42
has been conducted in order to inform the HOME initiative’s consensus discussions on how long-term control43
has been captured in previously published randomized controlled trials (RCTs). It represents stage 1 on the44
HOME Roadmap5 namely to identify available outcome instruments for capturing the domain of interest.45
46
METHODS47
This systematic review was performed according to PRISMA recommendations 6. The protocol was agreed48
prior to starting the review, and registered online (October 6, 2014)49
(http://nottingham.ac.uk/research/groups/cebd/documents/researchdocs/ltc-protocol-final.pdf).50
51
Eligibility criteria and search strategy52
We searched for RCTs with at least a 3-month follow-up period7 that included adults or children with AD, and53
which were published between January 1, 2000 and March 12, 2013. This period was chosen as prior to 2000,54
most AE trials were of relatively short duration.8 Eligible studies were identified using the Global Resource of55
Eczema Trials (GREAT) database (www.greatdatabase.org.uk). This freely available online database contains56
4records of RCTs for AD treatments found within MEDLINE, EMBASE, CINHAL, AMED, LILACS, the Cochrane57
Library and the Skin Group Specialised Register databases.58
59
The search strategy used to identify RCTs in the GREAT database and validation of the GREAT database have60
been published elsewhere.9 Observational studies were not included in this review due to time and resource61
limitations.62
63
Study selection and data extraction64
Inclusion criteria were predefined. Studies were included if the duration of patient follow-up was ≥3 months, 65
and a clinician or patient-reported outcome measure was recorded at three or more time points. We excluded66
studies that were published in abstract form only, those which did not include clinical outcomes (e.g. studies67
only containing data pertaining to biomarkers or skin barrier function tests), and those that were not published68
in English. Titles of studies were retrieved and the full-text was then obtained and screened against the69
inclusion criteria by two authors (NR, SB). Responses were compared and discrepancies resolved by consensus70
(NR, SB).71
72
Studies which met the inclusion criteria were divided between author pairs, who independently extracted data73
using a standardised data extraction form. Details were extracted for: (i) trial attributes (size of trial, age of74
participants); (ii) repeated measurement of clinician or patient-reported AD outcomes over time (iii) use of AD75
medication - defined as any treatment used to control AD symptoms other than the randomly allocated76
intervention; (iv) AD flares / relapse - defined as a decline in condition (worsening of symptoms) which met77
one of the recommended descriptions of flare3, regardless of whether ‘flare’, ‘relapse’ or ‘remission’ was78
specifically used within the text. For all long-term control outcomes, details of how the outcomes were79
recorded, analysed and presented in the paper were recorded. Data extraction forms were reviewed by80
another two authors (NR, SW), who checked for completeness and resolved any discrepancies by referring to81
the original trial publications.82
83
Results were summarised qualitatively, and the statistical techniques used in the original trial reports were84
reviewed by a medical statistician to ascertain the appropriateness of the analysis techniques used. The85
5analyses techniques described in the trial reports were categorised into “efficient analysis techniques” (best86
use of all available date); “inefficient analysis techniques” (statistically correct, but potentially inefficient use of87
available data); “inappropriate analysis techniques” (analysis of multiple time points individually without88
adjustment for multiple testing); or “unclear”.89
90
RESULTS91
A search of the GREAT database for studies published between 1 January 2000 and 12 March 2013 yielded a92
total of 353 RCTs (Fig1 and Appendix). Overall, 101 trials were included in the review (67% included either93
children or adults, 31% included both children and adults, one trial did not state the ages of the participants94
involved). Nearly all trials were conducted in a secondary or tertiary care setting.95
96
Types of long-term control outcomes used97
Long-term control outcomes were measured in a variety of ways, and 72 (71.2%) trials measured long-term98
control in two or more ways. In 92 trials (91%) repeated measurements of clinical or patient-reported99
outcomes were reported, in 26 trials (25.7%) AD flares were captured as an outcome measure, and in 29 trials100
(28.7%) the use of AD medication was used to measure long-term control. In all cases there was considerable101
heterogeneity in how the outcomes were defined and captured.102
Of the studies assessed, 68/101 (67.3%) had at least one graphical representation of long term data.103
6Repeated measurement of AE outcomes104
A total of 196 outcomes were used in the 92 trials that reported repeated measurement of AD outcomes105
(median 1.9 per trial) (Figure 2). The most commonly used outcomes were: SCORAD or objective SCORAD106
(25%), quality of life scales (14%), pruritus scales (10%), Body Surface Area (BSA) (8%), EASI or modified EASI107
(8%) and Investigator Global Assessment (IGA) (7%). As previously shown, there was large variability in IGA108
definitions between studies10 . The breakdown of clinician-reported and patient-reported outcomes is109
summarised in Figure 3.110
111
Outcomes were most often collected on a monthly basis (40% monthly, 27% more than a month apart, 25%112
irregular intervals, 6% weekly, 0.5% daily). Most trials (66/92, 71%) collected the outcomes between 3 and 5113
times over the duration of the trial, with 11 trials including 11 or more data collection points.114
115
Medication use116
The use of AD medications as an indicator of disease control (rather than adherence with study medications),117
was collected by less than a third of included trials (29/101), and only four reported this information as a118
primary outcome. Topical corticosteroid use was assessed in all 29 of these trials, but some trials also119
monitored other types of medication, including: antibiotics (n = 5); antihistamines (n = 5); calcineurin inhibitors120
(n =4); emollients (n = 2); and systemic therapy (n = 2). Information was documented solely during visits for121
just over half of the studies (15/29, 52%), with a minority collecting data on medication use from participant122
diaries (4/29, 14%), or a combination of clinic visits and participant diaries (3/29, 10%). The remaining studies123
did not give any details about the collection method (7/29, 24%). None of the included trials that provided124
details of data collection gathered information from medical notes. The manner in which medication use was125
captured varied considerably and included measurement of frequency of application, amount of medication126
used and potency (Figure 4).127
128
AD flares129
For 26/101 (25%) included trials, the concept of disease flares (including relapse / remission) was captured,130
and for 15 (58%) of these, flare outcomes were the primary outcome. In line with previously suggested131
categorisations for flare outcomes3, 9/26 (35%) used an arbitrary cut-off such as a change in score from a132
7baseline measurement (e.g IGA>4 or SCORAD>75% of baseline) , 6/26 (23%) used a behavioural measure such133
as the need for stepping-up topical steroid treatment (rescue medication) according to the patient or the134
physician, 9/26 (35%) used a composite measure (e.g IGA>4 AND the need for recue medication), and 2/26135
(7%) were classed as other/unknown. Data on flares was most commonly collected during clinic visits (14/26,136
53%), with only 6/26 (23%) being collected from participants at home.137
138
Most trials analysed flares in multiple ways, with a total 52 analyses performed (Table 1). Time to first flare139
was the most commonly used summary measure (21/52 analyses), followed by number of flares (17/52140
analyses).141
142
Data analysis techniques used143
Despite considerable efforts having been taken to collect long-term control outcome data throughout these144
trials, only 72/196 (37%) of the reported analyses made best use of the available data and included all time145
points in the analysis (Table 2). Analyses that were considered to be best use of the data included: ANOVA (n =146
35 analyses), linear mixed model (n=13 analyses), ANCOVA (n=12 analyses), nonlinear mixed model (n=2147
analyses), non-parametric repeated measures (n=2 analyses), area under the curve (n=1 analysis), log-rank test148
(n=1 analysis), McNemar (n=1 analysis), other (n=5 analyses).149
150
151
8DISCUSSION152
Main findings153
This review shows how previous researchers have tackled the measurement of long-term control in published154
RCTs of AD treatments, and serves to highlight some of the complexities of measuring disease control over155
time.156
Since almost all of the trials used repeated measurement of clinician or patient-reported outcomes over time,157
it would appear that such an approach is both feasible and acceptable. However, appropriate analysis of these158
data is challenging, and few trials reported their results in the most appropriate and efficient manner. The159
analysis of repeated measures requires the use of specific statistical tests (such as ANOVA, ANCOVA or mixed160
models).Using multiple tests to compare data between groups at each time points leads to increased risk of161
identifying a significant difference by chance. The fact that 39.7% of the reported analyses described in this162
review were performed using inappropriate statistical techniques, such as repeated significance testing at163
multiple time points (without adjustment for multiple testing),11 is something that the dermatology research164
community and academic journals could do more to address.165
166
We chose to report medication usage and analysis of flares separately. However, these concepts are often167
linked, as incidence of flares may be inversely related to the amount of anti-inflammatory medication used,168
and flare definitions commonly rely on the concept of escalation of therapy as an indicator of worsening169
disease.12 Similarly, worsening disease severity as captured by validated severity scales used repeatedly over170
time are likely to be capturing disease flares as experienced at specific time points. Further work is required to171
establish whether choosing one option over another is likely to miss a fundamental aspect of disease control172
that is important to patients.173
174
In considering the suitability of different methods for capturing long-term control, several issues are relevant.175
The need for chosen outcomes to be feasible in all trial settings is crucial when selecting measurement176
instruments for a core outcome set, and this can be a particular challenge when evaluating long-term control,177
which can be resource intensive and difficult to interpret.12178
179
9Equally important is the concept that outcomes should be relevant to patients with all severities of disease and180
healthcare settings. Most AD patients are treated in primary care and have relatively mild disease. As such,181
many patients are controlled with emollients only and rarely experience severe flares. In this setting, judging182
treatment response based on the amount of topical corticosteroid used, or the number of flares experienced183
over periods of a few months is unlikely to be an efficient trial design due to low event rates. Similarly, for184
patients with very severe disease who require systemic medication, or who experience fewer fluctuations in185
their disease severity, the concept of disease flares defined by topical corticosteroid use or flares may be less186
useful.187
188
The optimum frequency of outcome assessments (e.g. daily, weekly, monthly or bi-monthly) has yet to be189
established, and will no doubt be determined by the feasibility of outcome assessments. For patient-reported190
outcomes, more frequent data collection may be possible through the use of ‘apps’ or other on-line data191
collection tools13, thus facilitating data collection between clinic visits. By contrast, long-term control192
measured by independent observers during clinic visits or at participants’ homes, will by necessity limit the193
number and timing of outcome assessments.194
195
As a chronic, relapsing condition, AD has many similarities with other inflammatory conditions such as asthma196
and rheumatoid arthritis, where considerable efforts are now being made to establish working definitions for197
disease flares.14-17 An agreed definition of disease flare (or remission), as part of the outcome domain for long-198
term control would be a helpful step forward, and consistency in assessing AD long term control in RCTs and199
observational studies will improve the comparability of research, thus benefitting patients and health care200
providers. It is also salutatory that over half of the identified trials had to be excluded from this review as they201
were of less than 3 months’ duration, making assessment of long-term control impossible.202
203
Strengths and limitations204
This review sought to summarise the current approaches used in previously published AD RCTs to capture205
long-term control of AD. However, this approach means that more recent trends in data collection may have206
been missed as the included trials will all have been conceived and designed several years ago. Similarly, by207
excluding observational studies, it is possible that alternative means of capturing long-term control of AD have208
10
been missed. This review was also unable to comment directly on the feasibility of different approaches, or on209
the practical difficulties encountered from the methods used.210
211
What does this mean for the HOME initiative and for future research212
This systematic review has been conducted on behalf of the Long-Term Control Working Group for the HOME213
initiative and represents the first step in defining how best to measure long-term control in clinical trials as214
part of the core outcome set for AD. A review of validation studies that have evaluated outcomes for long-215
term control will be conducted, along with a suite of studies to address known research gaps, including validity216
and responsiveness of different approaches to capturing long-term control, and the optimum timing of217
outcome assessments.218
219
The HOME initiative has already achieved international consensus that clinical signs should be captured using220
the Eczema Area and Severity Index (EASI)7, 18 and that patient-reported symptoms should be captured using221
the Patient Oriented Eczema Measure (POEM). As such, in the absence of an agreed instrument for capturing222
long-term control, we recommend an ‘interim solution’ of using at least one of these scales at multiple time223
points (preferably at least monthly for a minimum of 3 months). The analysis of the data should be done using224
appropriate statistical techniques that take into account all time points in a single analysis. If possible, it would225
be ideal to use the HOME core outcome instruments for signs and symptoms alongside measures of disease226
flare or topical medication use, as this would provide additional data to inform future consensus agreement227
over the best way to measure long-term control.228
229
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Analysis Number
Time to first flare 21
Number of flares 17
Duration of remission 5
Duration of flare 4
“Totally controlled weeks” and “well controlled weeks” 1
Other 4
Appropriateness of analysis Category Number (%)
Best use of data Took into account all time points in single analysis 73 (37.2)
Inefficient analysis Only compared baseline and end point 30 (15.3)
Inefficient analysis Only data at a single time point is assessed 4 (2.0)
Inappropriate analysis Compared each time point to baseline individually 71 (36.2)
Inappropriate analysis Compared groups at each individual time point 7 (3.5)
Not analysable Unclear 11 (5.6)
Figure 1: LTC Flow diagram 
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